We initiated a phase I clinical trial of unasnemab (MT-3921) for HAM patients in 2022 (ClinicalTrials.gov NCT05240612), to primarily evaluate safety and pharmacokinetics of MT-3921 and assess whether RGMa inhibition leads to a reduction in neuronal damage and symptom amelioration. This evidence concerns the gene RGMA and tropical spastic paraparesis.